Relay Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Relay Therapeutics, Inc. (RLAY) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- Relay Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Relay Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- Relay Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- Relay Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $6.91M.
- Relay Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $46.63M.
- Relay Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $819.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $6.91M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.91M 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $6.91M 10-Q · filed 2026-08-06 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $46.63M 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $46.63M 10-Q · filed 2023-11-02 | |||
| 2020-12-31 | $819.00K 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |